Lawmakers criticize agencies for lack of coordination of prescription drug benefits for federal retirees

NewsGuard 100/100 Score

A lack of coordination between CMS and the Office of Personnel Management on prescription drug benefits for federal retirees has cost those retirees and the federal government as much as $200 million annually, according to a letter sent to the agencies on Monday by two House Democrats, CQ HealthBeat reports.

In the letter, House Oversight and Government Reform Committee Chair Henry Waxman (D-Calif.) and Rep. Danny Davis (D-Ill.) wrote that, for the more than 200,000 federal retirees who have prescription drug benefits through the Federal Employees Health Benefits Program and Medicare, the "additional Part D benefits are duplicative and unnecessary." According to the letter, the problem has resulted in $60 million in "unnecessary premiums paid by retirees" and $140 million in "unnecessary subsidies paid by taxpayers," and, in large part, "this $200 million represents excess profits for the private insurers that run the drug plans."

The letter asked CMS and OPM to provide information on the number of federal retirees enrolled in FEHBP and the Medicare prescription drug benefit, the plans in which those retirees are enrolled and an analysis of the cost of the "duplicative coverage" for those retirees and the federal government.

CMS spokesperson Jeff Nelligan said that agency officials have begun to review the letter. OPM spokesperson Mike Orenstein said that he could not confirm whether agency officials had received the letter, adding that they would respond to the lawmakers directly (Carey, CQ HealthBeat, 5/12).


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
When it comes to ketamine, Meta’s posting policy is no party to decipher